Valuation: SELLAS Life Sciences Group, Inc.

Market Cap 2.36B 2.04B 1.91B 1.75B 3.29B 225B 3.34B 22.38B 8.78B 113B 8.87B 8.67B 372B P/E 2026 *
-57.2x
P/E 2027 * -96.1x
Enterprise Value 2.36B 2.04B 1.91B 1.75B 3.29B 225B 3.34B 22.38B 8.78B 113B 8.87B 8.67B 372B EV / Sales 2026 *
-
EV / Sales 2027 * 44.5x
Free-Float
99.05%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SELLAS Life Sciences Group, Inc.

1 day+2.65%
1 week+19.98%
Current month+19.98%
1 month-11.04%
3 months+143.61%
6 months+221.98%
Current year+218.57%
1 week 9.8
Extreme 9.8
12.21
1 month 9.19
Extreme 9.19
14.86
Current year 3.23
Extreme 3.23
15.88
1 year 1.39
Extreme 1.39
15.88
3 years 0.5
Extreme 0.4986
15.88
5 years 0.5
Extreme 0.4986
15.88
10 years 0.5
Extreme 0.4986
554.5
Manager TitleAgeSince
Chief Executive Officer 50 29/12/2017
Director of Finance/CFO 41 30/12/2017
Compliance Officer - -
Director TitleAgeSince
Director/Board Member 50 29/12/2017
Chairman 66 01/06/2024
Director/Board Member 69 29/12/2017
Date Insider Type Main position Quantity % Market Cap.
07/01/26 Free

Executive/Senior Manager

300,000 0.2106%
07/01/26 Free

Director

50,000 0.0351%
07/01/26 Free

Chief Financial Officer

300,000 0.2106%
Change 5-day change 1-year change 3-year change Capi.($)
+2.65%+19.98%+650.62%+677.35% 2.36B
+8.49%+20.55%+69.74%+109.30% 68.12B
+1.25%+2.44%+32.55%+72.63% 55.18B
-1.09%+32.96%+19.95%+499.45% 28.63B
+2.72%+3.41%-15.88%-4.90% 23.53B
+10.83%+18.38%+52.76%+4.58% 23.99B
+6.50%+7.56%+38.20%-21.33% 18.45B
-3.88%+16.98%+199.30%+354.30% 15.83B
+6.20%+11.51%+34.94%+681.88% 16.44B
+3.58%+1.96%+44.61%+167.01% 13.4B
Average +3.72%+12.51%+112.68%+254.03% 26.59B
Weighted average by Cap. +4.34%+13.16%+54.82%+173.01%

Financials

2026 *2027 *
Net sales - 53.09M 45.93M 42.89M 39.34M 74M 5.05B 75.18M 503M 197M 2.53B 199M 195M 8.37B
Net income -37.97M -32.85M -30.68M -28.14M -52.93M -3.61B -53.77M -360M -141M -1.81B -143M -139M -5.99B -26.29M -22.74M -21.23M -19.48M -36.64M -2.5B -37.22M -249M -97.78M -1.25B -98.71M -96.55M -4.15B
Net Debt - -
Logo SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Employees
-
Date Price Change Volume
07/08/26 $12.01 +2.65% 5,124,094
06/08/26 $11.70 -1.35% 3,769,705
05/08/26 $11.86 +0.42% 5,763,731
04/08/26 $11.81 +5.26% 5,089,754
03/08/26 $11.22 +12.09% 6,968,504
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
12.01USD
Average target price
27.50USD
Spread / Average Target
+128.98%

Quarterly revenue - Rate of surprise